Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to -$2.0 million.

  • GeneDx Holdings' Change in Accured Expenses fell 16573.11% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 4969.35%. This contributed to the annual value of -$20.5 million for FY2024, which is 5642.24% up from last year.
  • GeneDx Holdings' Change in Accured Expenses amounted to -$2.0 million in Q3 2025, which was down 16573.11% from -$3.6 million recorded in Q2 2025.
  • In the past 5 years, GeneDx Holdings' Change in Accured Expenses ranged from a high of $42.3 million in Q2 2022 and a low of -$14.5 million during Q3 2023
  • For the 5-year period, GeneDx Holdings' Change in Accured Expenses averaged around -$97578.9, with its median value being -$5.1 million (2021).
  • Within the past 5 years, the most significant YoY rise in GeneDx Holdings' Change in Accured Expenses was 2151140.86% (2021), while the steepest drop was 2646584.48% (2021).
  • Quarter analysis of 5 years shows GeneDx Holdings' Change in Accured Expenses stood at $21.0 million in 2021, then tumbled by 71.88% to $5.9 million in 2022, then tumbled by 219.28% to -$7.0 million in 2023, then crashed by 79.74% to -$12.7 million in 2024, then soared by 84.08% to -$2.0 million in 2025.
  • Its Change in Accured Expenses stands at -$2.0 million for Q3 2025, versus -$3.6 million for Q2 2025 and $10.8 million for Q1 2025.